Clinical Trial Update: Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study [Phase 3]

View source ↗

Summary

Immunogenicity and safety data for the fourth dose of LBVH0101 in LG Life Sciences' LG-VHCL002 Phase 3 Hib vaccine study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• LBVH0101

Snippet

Sponsor: LG Life Sciences | Conditions: Infectious Disease by Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED